Denis chem lab Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory requirements under SEBI depositories regulations. The pharmaceutical manufacturer submitted the mandatory documentation for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The company submitted its certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited on April 6, 2026. The filing was signed by Anal Desai, Company Secretary and Compliance Officer of Denis Chem Lab Limited.

Registrar Confirmation

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued the compliance certificate as the company's registrar and share transfer agent. The certificate was dated April 1, 2026, and signed by Ashok Shetty, Sr. Vice President-Corporate Registry.

The registrar confirmed that securities received from depository participants for dematerialization during the quarter were properly processed within prescribed timelines. All security certificates received for dematerialization were confirmed or rejected appropriately, with certificates being mutilated and cancelled after due verification.

Company Background

Denis Chem Lab Limited operates as a manufacturer of parenteral products in the pharmaceutical sector. The company is incorporated with CIN L24230GJ1980PLC003843 and maintains its registered office in Ahmedabad, Gujarat.

The quarterly filing demonstrates the company's adherence to SEBI regulations governing depositories and participants, ensuring proper handling of dematerialized securities and maintaining transparency with stock exchange authorities.

Denis Chem Lab Limited has received multiple disclosures under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding significant shareholding changes. The latest disclosure under Regulation 29(1) from Varun Daga Family Trust confirms the coordinated acquisition structure that resulted in aggregate holdings of 9.64% in the company.

Varun Daga Family Trust Disclosure

Varun Daga Family Trust, acting as trustee through Varun Daga, filed a disclosure under Regulation 29(1) on March 30, 2026, confirming their substantial acquisition in Denis Chem Lab Limited. The trust acquired 2,67,499 equity shares representing 1.93% of the company's paid-up equity share capital through an off-market transaction completed on March 27, 2026.

Coordinated Acquisition Structure

The acquisition involved a coordinated effort between Varun Daga Family Trust as the acquirer and persons acting in concert including Shreans Daga Family Trust and Kanchan Daga. The aggregate acquisition resulted in total holdings of 13,37,498 equity shares representing 9.64% of the company's share capital.

Previous Holdings and Transaction Details

According to the regulatory disclosure, Varun Daga Family Trust had no previous holdings in Denis Chem Lab Limited before this acquisition. The trust's holdings increased from nil to 2,67,499 equity shares through the off-market transaction, establishing their 1.93% stake in the company.

Company Share Capital Structure

Denis Chem Lab Limited's equity share capital structure remained unchanged throughout these transactions. The company maintains its listing on BSE Limited with consistent share capital parameters as confirmed in the regulatory disclosures.

Regulatory Compliance

All disclosures were made in strict accordance with SEBI regulations. The Varun Daga Family Trust's Regulation 29(1) disclosure established the substantial shareholding acquisition through coordinated action with persons acting in concert. All parties confirmed they do not belong to the promoter or promoter group category, and all transactions involved only equity shares carrying voting rights with no encumbrances.